Loading...
•
Jun 30
Absci Q2 2025 Earnings Report
Absci reported a wider net loss in Q2 2025 amid increased R&D investment, while bolstering its financial position with a $64M raise in July.
Key Takeaways
Absci's Q2 2025 results showed ongoing execution across internal and partnered pipelines. Despite a drop in revenue and a higher net loss, the company strengthened its balance sheet, extending runway into 2028.
Q2 revenue declined to $0.6M from $1.3M YoY
Net loss widened to $30.6M driven by higher R&D spending
Raised $64M in July to support operations through H1 2028
Expanded collaboration with Almirall and progressed internal assets ABS-101 and ABS-201
Absci
Absci
Absci Revenue by Segment
Revenue by Segment
Partner program Revenue
CapyFin.com Forward Guidance
Absci expects continued progress in clinical and preclinical development, further collaborations, and operational stability through 2028.
Positive Outlook
- Raised $64M in July 2025 through equity offerings
- Cash runway extended into H1 2028
- ABS-101 Phase 1 interim data expected in H2 2025
- ABS-201 expected to enter Phase 1/2a in early 2026
- Ongoing platform scaling through AMD partnership
Challenges Ahead
- Revenue decreased YoY from $1.3M to $0.6M
- Net loss increased to $30.6M
- Higher R&D expenses drove greater burn
- Ongoing reliance on external funding
- Operating losses continue with no near-term profitability